316 related articles for article (PubMed ID: 26984934)
1. Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect.
Nagakari K; Emmi M; Iba T
Clin Appl Thromb Hemost; 2017 Sep; 23(6):677-684. PubMed ID: 26984934
[TBL] [Abstract][Full Text] [Related]
2. Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect.
Iba T; Emmi M; Hiki M; Nagayama M; Aihara K; Tabe Y; Yuri M; Ohsaka A
Int J Hematol; 2016 Jun; 103(6):665-72. PubMed ID: 26984594
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
4. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
5. Laboratory measurement of the direct oral anticoagulants.
Dale BJ; Chan NC; Eikelboom JW
Br J Haematol; 2016 Feb; 172(3):315-36. PubMed ID: 26492202
[TBL] [Abstract][Full Text] [Related]
6. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
[TBL] [Abstract][Full Text] [Related]
7. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
Platton S; Hunt C
Int J Lab Hematol; 2019 Apr; 41(2):227-233. PubMed ID: 30468572
[TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
Dale BJ; Ginsberg JS; Johnston M; Hirsh J; Weitz JI; Eikelboom JW
J Thromb Haemost; 2014 Nov; 12(11):1810-5. PubMed ID: 25196577
[TBL] [Abstract][Full Text] [Related]
10. Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients.
Mahamad S; Chaudhry H; Nisenbaum R; McFarlan A; Rizoli S; Ackery A; Sholzberg M
J Thromb Thrombolysis; 2019 Feb; 47(2):272-279. PubMed ID: 30506352
[TBL] [Abstract][Full Text] [Related]
11. In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.
Körber MK; Langer E; Kaufner L; Sander M; Von Heymann C
Blood Transfus; 2016 Sep; 14(5):481-6. PubMed ID: 27177413
[TBL] [Abstract][Full Text] [Related]
12. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
[TBL] [Abstract][Full Text] [Related]
13. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
[TBL] [Abstract][Full Text] [Related]
14. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
[TBL] [Abstract][Full Text] [Related]
15. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
[TBL] [Abstract][Full Text] [Related]
16. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.
Schmidt K; Krüger K; Langer E; Schmutzler M; Johnen E; Wernecke KD; von Heymann C; Körber MK
Blood Transfus; 2019 Mar; 17(2):157-162. PubMed ID: 29757137
[TBL] [Abstract][Full Text] [Related]
17. The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.
Brown KS; Wickremasingha P; Parasrampuria DA; Weiss D; Kochan J; Dishy V; He L; Shi M
Thromb Res; 2015 Oct; 136(4):825-31. PubMed ID: 26298619
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
[TBL] [Abstract][Full Text] [Related]
20. Management of bleeding in patients treated with direct oral anticoagulants.
Levi M
Crit Care; 2016 Aug; 20():249. PubMed ID: 27543264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]